23andMe launches new genetic report on osteoporosis
Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
Nature9d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
pharmaphorum3d
Troubled 23andMe is exploring a sale of the business
Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...
23andMe announces continued concerns regarding liquidity
Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...
Stocks to Watch: 23andMe, Manhattan Associates, Nextracker
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...